Immunotherapy for Squamous Non-Small Cell Lung Cancer
0 Views
administrator
07/14/23
http://cancerGRACE.org/
The immune checkpoint inhibitor nivolumab has been shown in the CheckMate 017 trial to lead to better response rates, survival, and better tolerability than docetaxel (Taxotere) chemotherapy. But can we predict which patients will do best?
-
Category
Show more
Facebook Comments
No comments found